{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:41:03Z","timestamp":1792082463803,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.pnpbp.2008.02.013","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T20:38:26Z","timestamp":1205181506000},"page":"1191-1194","source":"Crossref","is-referenced-by-count":36,"title":["Extended release carbamazepine in the treatment of pathological gambling: An open-label study"],"prefix":"10.1016","volume":"32","author":[{"given":"Donald W.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha C.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2008.02.013_bib1","series-title":"Diagnostic and statistical manual of mental disorders, fourth edition text revision","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1176\/ps.49.11.1434","article-title":"Clinical features and psychiatric comorbidity in 30 subjects reporting pathological gambling behavior","volume":"49","author":"Black","year":"1998","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00005053-200302000-00011","article-title":"Quality of life and family history in pathological gambling","volume":"191","author":"Black","year":"2003","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.jcp.0000114844.58996.4a","article-title":"An open-label trial of bupropion in the treatment of pathological gambling","volume":"24","author":"Black","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.jcp.0000264985.25109.25","article-title":"Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study","volume":"27","author":"Black","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/wnf.0b013e31803d357f","article-title":"An open label study of escitalopram in the treatment of pathological gambling","volume":"30","author":"Black","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib7","first-page":"44","article-title":"A pilot placebo-controlled study of fluvoxamine for pathological gambling","volume":"63","author":"Blanco","year":"2002","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1360-0443.1991.tb01782.x","article-title":"Control versus abstinence in the treatment of pathological gambling: a two to nine year follow up","volume":"86","author":"Blaszczynski","year":"1991","journal-title":"Br J Addict"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/scnp.2001.22919","article-title":"The epidemiology of pathological gambling","volume":"6","author":"Cunningham-Williams","year":"2001","journal-title":"Sem Clin Neuropsychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wnf.0000152623.46474.07","article-title":"Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study","volume":"28","author":"Dannon","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/14750708.2.5.753","article-title":"Sustained-release bupropion in the treatment of SSRI nonresponder pathologic gamblers: pilot study and review of the literature","volume":"2","author":"Dannon","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.jcp.0000186867.90289.ed","article-title":"Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study","volume":"25","author":"Dannon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib13","series-title":"Third International Conference on OCD, Madeira, Portugal, September","article-title":"Reliability and validity of a pathological gambling Modification of the Yale-Brown Obsessive\u2013Compulsive Scale: Preliminary findings","author":"DeCaria","year":"1998"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study","volume":"66","author":"Grant","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004850-200307000-00007","article-title":"Paroxetine treatment of pathological gambling: a multi-center randomized controlled trial","volume":"18","author":"Grant","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label study with double-blind discontinuation","volume":"21","author":"Grant","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib19","series-title":"ECDEU assessment manual for psychopharmacology","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2007-1014292","article-title":"Treatment of pathological gambling with carbamazepine (letter)","volume":"27","author":"Haller","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0193-953X(05)70185-4","article-title":"Pathological gambling","volume":"23","author":"Hollander","year":"2000","journal-title":"Psychiatr Clin NA"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0006-3223(00)00241-9","article-title":"A randomized double-blind fluvoxamine\/placebo crossover trial in pathological gambling","volume":"47","author":"Hollander","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10899-004-1932-8","article-title":"Pharmacologic treatment of pathological gambling","volume":"21","author":"Hollander","year":"2005","journal-title":"J Gambling Stud"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1176\/appi.ajp.162.1.137","article-title":"Does sustained- release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?","volume":"162","author":"Hollander","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4088\/JCP.v63n0606","article-title":"A double-blind placebo controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib28","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/ajp.144.9.1184","article-title":"The South Oaks Gambling Screen (SOGS): a new instrument for identification of pathological gamblers","volume":"144","author":"Lesieur","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0010-440X(96)90001-2","article-title":"Are impulse-control disorders related to bipolar disorder ?","volume":"37","author":"McElroy","year":"1996","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib30","first-page":"785","article-title":"Lithium and lady luck: use of lithium carbonate in compulsive gambling","volume":"80","author":"Moskowitz","year":"1980","journal-title":"NY State J Med"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib31","series-title":"Gambling impact and behavior study, report to the national gambling impact study commission","author":"National Opinion Research Center at the University of Chicago (NORC)","year":"1999"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib32","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1136\/jnnp.2004.036863","article-title":"Antiepileptic drugs in psychiatry","volume":"75","author":"Ovsiew","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v63n0704","article-title":"Lithium and valproate treatment of pathological gambling: a randomized single-blind study","volume":"63","author":"Pallanti","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4088\/JCP.v63n1114","article-title":"Nefazodone treatment of pathological gambling: a prospective open-label controlled trial","volume":"63","author":"Pallanti","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00005053-200207000-00007","article-title":"Suicide ideation and attempts in treatment-seeking pathological gamblers","volume":"190","author":"Petry","year":"2002","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib36","series-title":"A Structured Interview for DSM-IV Personality (SIDP-IV)","author":"Pfohl","year":"1997"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib37","series-title":"The anxiety disease","author":"Sheehan","year":"1986"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib38","series-title":"Alcohol time line followback users manual","author":"Sobell","year":"1995"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib39","series-title":"Structured Clinical Interview for DSM-IV","author":"Spitzer","year":"1994"},{"key":"10.1016\/j.pnpbp.2008.02.013_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4088\/JCP.v63n0109","article-title":"An open-label study of citalopram in the treatment of pathological gambling","volume":"63","author":"Zimmerman","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584608000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584608000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,5]],"date-time":"2021-09-05T15:38:16Z","timestamp":1630856296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584608000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0278584608000766"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2008.02.013","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}